Quantitative Cell-Based Bioassays for Individual or Combination Immune Checkpoint Immunotherapy
Part # PS290
Jamison Grailer, Pete Stecha, Julia Gilden, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong and Zhi-jie Jey Cheng
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711
Immunotherapy aims to boost a patient’s own immune system to fight disease. Activation of T cells via direct stimulation of the T cell receptor or by modulating immune checkpoint pathways are two strategies being employed individually and in combination. Immune checkpoint targets include co-inhibitory (e.g. PD-1, CTLA-4, TIGIT, LAG-3) and co-stimulatory (e.g. GITR, 4-1BB, OX40, CD40) receptors. Here we describe the application of cell-based reporter bioassays for the development of therapeutic antibodies targeting co-inhibitory immune checkpoint receptors.
Printed in USA.